Cytokinetics vs Roivant Sciences
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Cytokinetics and Roivant Sciences side by side, using each oneβs latest annual report. Here is what stands out:
- Cytokinetics is the larger business, with $88.0M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 11 times as much.
- Cytokinetics grew revenue faster (376.6%, against β71.6%).
- Cytokinetics kept more of each dollar of sales as operating profit (β695.4% operating margin, against β6,235.7%).
- Cytokinetics turned more of its sales into free cash flow (β607.5% FCF margin, against β9,183.5%).
Who comes out ahead
Of the 5 measures where higher (or lower) is clearly better, how many each company leads.
Cytokinetics
CYTK
5/5
Revenue growth5-year growthOperating marginNet marginFCF margin
Roivant Sciences
ROIV
0/5
Side by side
Best in the row
| Latest fiscal year | CYTK FY25 | ROIV FY25 |
|---|---|---|
| Size | ||
| Market cap | β | $26.3B |
| Revenue | $88.0M | $8.3M |
| Free cash flow | β$535M | β$759M |
| Net income | β$785M | β$300M |
| Growth | ||
| Revenue growth | 376.6% | β71.6% |
| 5-year growth | 9.5% | β19.0% |
| Share count change | β | β4.4% |
| Profitability | ||
| Gross margin | β | β |
| Operating margin | β695.4% | β6,235.7% |
| Net margin | β891.6% | β3,629.2% |
| FCF margin | β607.5% | β9,183.5% |
| Return on capital | β | β62.6% |
| Return on equity | β | β6.5% |
| Balance sheet | ||
| Net debt | β$912M | β$4.3B |
| Net debt / EBITDA | β | β |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | β | β |
| Piotroski F-score | β | 1 |
Ten years
Revenue
FY16
CYTK $106M
ROIV β
FY17
CYTK $13.4M
ROIV β
FY18
CYTK $31.5M
ROIV β
FY19
CYTK $26.9M
ROIV β
FY20
CYTK $55.8M
ROIV $23.8M
FY21
CYTK $70.4M
ROIV $55.3M
FY22
CYTK $94.6M
ROIV $31.5M
FY23
CYTK $7.5M
ROIV $32.7M
FY24
CYTK $18.5M
ROIV $29.1M
FY25
CYTK $88.0M
ROIV $8.3M
CYTK
ROIV
Operating margin
FY16
CYTK 17.6%
ROIV β
FY17
CYTK β848.3%
ROIV β
FY18
CYTK β282.3%
ROIV β
FY19
CYTK β368.0%
ROIV β
FY20
CYTK β168.3%
ROIV β4,500.5%
FY21
CYTK β264.5%
ROIV β2,444.8%
FY22
CYTK β342.8%
ROIV β2,875.9%
FY23
CYTK β6,589.7%
ROIV 13,746.9%
FY24
CYTK β2,902.7%
ROIV β3,453.3%
FY25
CYTK β695.4%
ROIV β6,235.7%
CYTK
ROIV
Free cash flow
FY16
CYTK $35.4M
ROIV β
FY17
CYTK β$105M
ROIV β
FY18
CYTK β$102M
ROIV β
FY19
CYTK β$93.5M
ROIV β
FY20
CYTK β$2.1M
ROIV β$558M
FY21
CYTK β$191M
ROIV β$695M
FY22
CYTK β$311M
ROIV β$856M
FY23
CYTK β$416M
ROIV β$767M
FY24
CYTK β$400M
ROIV β$844M
FY25
CYTK β$535M
ROIV β$759M
CYTK
ROIV
Return on capital
FY16
CYTK β
ROIV β
FY17
CYTK β
ROIV β
FY18
CYTK β
ROIV β
FY19
CYTK β
ROIV β
FY20
CYTK β
ROIV β
FY21
CYTK β
ROIV β
FY22
CYTK β
ROIV β286.2%
FY23
CYTK β
ROIV β
FY24
CYTK β
ROIV β
FY25
CYTK β
ROIV β62.6%
CYTK
ROIV
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.